Analysis of HLA-I expression on circulating B lymphocytes of CLL subjects with stable disease revealed a significant reduction in HLA-A (37.49 ± 5.77 vs. 104.9 ± 27.81 in healthy controls; p < 0.005), HLA-BC (47.58 ± 7.25 vs. 128.4 ± 38.57 in controls; p < 0.05) and β2-microglobulin surface level (54.29 ± 8.96 vs. 156.81 ± 41.91 in healthy controls; p < 0.005) (Figure 5A). The gene discussed is HLA-A; the disease is breast cancer.